Vanderbilt Institute for Medicine and Public Health

HERO-TOGETHER is an opportunity for people working in health care who receive a COVID-19 vaccine to help the public understand how people do after vaccination. The COVID-19 pandemic is a once-in-a-generation challenge that health care heroes everywhere have worked together to face. From working on the front lines to working behind the scenes, people in healthcare and public service have joined together with unprecedented focus to fight COVID-19.

Younger parents were much less likely than older parents to say they planned to vaccinate their children and themselves against COVID-19, according to a research letter published online in medRxiv by authors at the Vanderbilt University School of Medicine and Ann & Robert H. Lurie Children’s Hospital of Chicago and Northwestern University Feinberg School of Medicine.

Findings from a national study published Nov. 9 in the Journal of the American Medical Association (JAMA) “do not support” the use of hydroxychloroquine for the treatment of adult patients hospitalized with COVID-19, the report concludes. The Outcomes Related to COVID-19 treated with Hydroxychloroquine among In-patients with symptomatic Disease (ORCHID) study found that, when compared to inactive placebo, hydroxychloroquine did not significantly improve clinical outcomes of patients hospitalized for respiratory illness related to COVID-19.

Graduates from Vanderbilt’s Master in Public Health (MPH) program didn’t plan to become front-line soldiers against the COVID-19 global pandemic, but several have found themselves putting their training — and their career goals — front and center.

Vanderbilt University Medical Center has been awarded a one-year, $34-million grant by the National Center for Advancing Translational Sciences, part of the National Institutes of Health, to conduct a nationwide study of “convalescent plasma” as a treatment for COVID-19. The randomized, controlled trial will test whether infusions of plasma, the liquid part of blood collected from COVID-19 survivors, can help other hospitalized patients with COVID-19. The plasma contains antibodies against SARS-CoV-2, the virus that causes COVID-19.

In a new analysis, researchers from the Department of Health Policy at Vanderbilt University School of Medicine and Vanderbilt University Medical Center have found a relationship between the growth of hospitalizations and masking requirements put in place across the state. Hospitals that have more than 75% of their patients from areas without masking requirements in place have seen a relatively faster increase in patients with COVID-19 than hospitals with higher percentages of patients from areas with masking requirements in place.

The effects of Covid-19 are here to stay, including in the brain, at least according to a new study by Mario Mazza and colleagues in the journal Brain, Behavior, and Immunity.

NASHVILLE, TENN. (WSMV) - A new survey out of Vanderbilt University is showing the toll the coronavirus pandemic is taking on our mental well-being.  Researchers polled parents with children under the age of 18 at the beginning of June.  They found that 27 percent of parents felt like their own mental health had worsened. 14 percent of those parents saw negative changes in their kids. 

Over the past six months, we have learned COVID-19 is not solely a lung disease, but a disease that involves the brain as well. Most patients with COVID-19 have delirium, which is the medical way of saying they are confused, can’t pay attention, and have trouble organizing their thinking.

The Critical Illness, Brain Dysfunction and Survivorship Center at Vanderbilt University Medical Center is following patients who have been hospitalized for COVID-19 over time to see if they develop long-term cognitive impairment, depression or post-traumatic stress disorder (PTSD). These disabling features suffered by millions of ICU survivors are called Post-Intensive Care Syndrome (PICS).

The ongoing disruptive changes from efforts to reduce the spread of COVID-19 are having a substantial negative impact on the physical and mental well-being of parents and their children across the country, according to a new national survey published today in Pediatrics.

Vanderbilt University Medical Center is evaluating razuprotafib, a drug being investigated for the treatment of glaucoma, in a new randomized, investigational trial for the prevention and treatment of acute respiratory distress syndrome (ARDS) in adult patients with moderate to severe COVID-19. “We urgently need to find effective treatments for COVID-19, especially for patients who develop severe lung injury from the virus,” said co-principal investigator Wesley Self, MD, an emergency medicine physician at Vanderbilt University Medical Center.